Nice try. But when I posted it was 8 institutional holders at about 795k shares. It's nice that the number of shares have increased and the number of institutional holders is increasing, hopefully that trend continues. But they really need to release forward progress with their drug trials.
Institutional investors can hype and flip like anyone else on the promise of a newly listed Nasdaq stock. But this company won't gain any trust back from me until they are officially in phase 1. Hope it happens, I still hold a grip of shares, but I also got profit out before the 200:1 r/s because too many things were looking shady. Sure enough they were because this thing has to hit $60 to equate to the previous high of $.30 from the OTC last year. $2 to $60 is a big jump to make even if they announced phase 1 trials.
News 
Market Data 
Discover 
AI
